Liposome

Congress: CLINAM, 23rd May 2011 – The development of new activatable drug nanocarriers, with multiple functionalities, presents a promising approach for cancer treatment. Improved drug delivery and controlled drug release at the tumor site may have considerable benefit by increasing treatment efficacy while reducing side effects and toxicity. Further, the possibility to monitor both nanocarrier accumulation and drug release via current clinical imaging techniques may be particularly relevant for an optimal treatment.

Continue Reading...